NHL

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Lymphoma, Patient, GBM, Artificial intelligence, Brain, Metadata, Pancreatic cancer, Lung cancer, Mantle cell lymphoma, Clinical trial, Therapy, Harmonic, ATM, USD, PD-1, MCL, DHL, Central nervous system, CNS, DNA, Starlight, Fox Chase Cancer Center, Glioblastoma, Cancer, Safety, Liquid biopsy, Calendar, ADC, TP53, NSCLC, ATRT, AI, AACR, Drug development, Machine learning, FDA, Annual general meeting, Incidence, Triple-negative breast cancer, NHL, Patent, Pharmaceutical industry

“This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.

Key Points: 
  • “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.
  • During the 4th quarter of 2023, Lantern filed 3 new patent applications culminating in 11 new patent applications for the calendar year 2023.
  • The cash burn rate for the 4th quarter and full year of 2023 continues to reflect our capital-efficient, collaborator-centered business model.
  • Full Year Net Loss: Net loss per share was $1.47 per share for the fiscal year 2023 compared to $1.31 per share for the fiscal year 2022.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Retrieved on: 
Friday, March 15, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, SOC, MCL, Index, DHL, Patient, Neoplasm, Artificial intelligence, AI, Sarcoma, Human, NHL, Mantle cell lymphoma, Clinical trial, Bone marrow, Safety, Pharmacokinetics, MTD, Machine learning, FDA, DLBCL, Pharmaceutical industry

“Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.

Key Points: 
  • “Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.
  • Patients will be enrolled and treated with LP-284 administered intravenously (IV) on Days 1, 8, 15 of a 28-day schedule.
  • Up to 30 patients will be enrolled in Phase 1a; the total number of patients will depend on the number of dose levels explored.
  • Additionally, Lantern may enroll up to 40 patients in each of the two cohorts of MCL and HGBL (including DLBCL) tumors in Phase 1b.

CBD Healthcare Company Becomes the First-Ever Worldwide to Earn Prestigious NSF International Certifications in Personal Care for Athletes (NSF Guideline 527 and NSF Certified for Sport)

Retrieved on: 
Friday, March 15, 2024
Sports, General Sports, Alternative Medicine, Other Health, Health, Cannabis, Specialty, Natural Resources, Cosmetics, Retail, Fitness & Nutrition, CFL, Solvent, Certification, Organization, Sport, Therapy, Dietary supplement, Risk, Senior ice hockey, National Hockey League, Good manufacturing practice, LPGA, Ironman, Selective androgen receptor modulator, AFL, Growth hormone, CBD, Massage, Athlete, NHL, GMP, Outline of health sciences, NSF, MLB, CCES, Diuretic, Former, USADA, Good, Sports medicine, Multimedia, NBA, PGA, THC, UFC, Steroid, NFL, NASCAR, Major League Baseball, Nursing

CBD Healthcare Company (CBDHCC) has become the First-Ever Personal Care Product to have earned certification to NSF Guideline 527 and NSF Certified for Sport® for its Broad-Spectrum CBD Balancing Massage and Body Oil.

Key Points: 
  • CBD Healthcare Company (CBDHCC) has become the First-Ever Personal Care Product to have earned certification to NSF Guideline 527 and NSF Certified for Sport® for its Broad-Spectrum CBD Balancing Massage and Body Oil.
  • "The spirit of clean athletic competition is something we all connect with,” said David Lonza, Vice President, Health Sciences at NSF.
  • NSF Certified for Sport® certifies dietary supplements, functional foods, cosmetics and personal care products to be free from substances banned by major sporting organizations.
  • Products Certified for Sport® must also be certified to either NSF/ANSI 173, NSF 229 or NSF 527 to ensure their contents match their claims.

Wasabi Adds Vancouver Canucks to its Growing Sports, Media & Entertainment Roster

Retrieved on: 
Tuesday, March 12, 2024
Technology, Data Management, Cloud, Health, Freedom, Sport, Boston Red Sox, Boston Bruins, Partnership, Education, Cloud storage, Publishing, Rogers Arena, Acquisition, Canucks Sports & Entertainment, M&E, NHL, Corporate social responsibility, Animation, API, Liverpool F.C., Entertainment, Hockey, Emotion, Television, Video game

Wasabi Technologies , the hot cloud storage company , has strengthened its sports, media & entertainment customer and partner portfolio with the addition of the National Hockey League’s (NHL) Vancouver Canucks.

Key Points: 
  • Wasabi Technologies , the hot cloud storage company , has strengthened its sports, media & entertainment customer and partner portfolio with the addition of the National Hockey League’s (NHL) Vancouver Canucks.
  • In a new partnership with Canucks Sports & Entertainment, Wasabi becomes the Preferred Cloud Storage of the Canucks with extensive branding integration for the 2024 NHL season, while the Canucks benefit operationally from Wasabi’s best-in-class cloud data storage services via a multi-year technology deal.
  • Wasabi hot cloud storage is purpose-built for sports and media & entertainment (M&E) workloads, offering more affordability, accessibility, and simplicity than competitors.
  • As the Preferred Cloud Storage of the Canucks, Wasabi’s brand will be prominently displayed throughout Rogers Arena, online and in-game broadcast moments.

TD Bank Celebrates 100 Years of The Boston Bruins with Centennial Pins

Retrieved on: 
Monday, March 11, 2024
Fashion, Professional Services, Hockey, Retail, Sports, Specialty, Banking, Delaware North, TD Garden, Bruin, Partnership, Toronto-Dominion Bank, Opening Night, Small business, NHL, Sports Museum, Region, Family, Payment card

TD Bank, America’s Most Convenient Bank® , today announced a special Boston Bruins commemorative pin giveaway celebrating 100 years of Boston Bruins hockey.

Key Points: 
  • TD Bank, America’s Most Convenient Bank® , today announced a special Boston Bruins commemorative pin giveaway celebrating 100 years of Boston Bruins hockey.
  • "As the bank of the Boston Bruins, TD Bank is proud to celebrate such an incredible milestone with some of the most passionate fans in New England and the NHL," said Sheryl McQuade, Regional President of the New England Metro, TD Bank.
  • “It’s an exciting time to be a Boston Bruins fan,” said Glen Thornborough, president of TD Garden and COO of the Boston Bruins.
  • Through the TD Bank Community Clubhouse initiative, TD Bank and the Bruins host community-based organizations with blocks of complimentary tickets at multiple games.

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Conference, Rituximab, B-cell lymphoma, Serum, HIO, Patient, CD20, Humoral immunity, Cancer, BRITE, NHL, AACR, CA125, ADC, Lymphoma, CD19, Vaccine

Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.

Key Points: 
  • Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.
  • Navrogen will present data showing NAV-006's superior efficacy over rituximab in animal models of human NHL.
  • "We have engineered a trastuzumab-drug conjugate variant with superior cytotoxicity against ICAM-1 positive cancer cells.
  • We are now building a portfolio of enhanced ADCs using this platform to advance internal as well as partnered ADC programs".

El Bandido Yankee Releases Authentic Small Batch Añejo Tequila "This Bandido's Done Time"

Retrieved on: 
Wednesday, April 3, 2024
Jelly roll, Friends, Laughter, Bandidos Motorcycle Club, Ageing, NHL, CO, Family, NFL, Hockey Hall of Fame, Liquor

After four years, El Bandido Yankee Tequila Company , an ultra-premium spirits brand, announces the launch of its third expression: Tequila Añejo.

Key Points: 
  • After four years, El Bandido Yankee Tequila Company , an ultra-premium spirits brand, announces the launch of its third expression: Tequila Añejo.
  • Sourced from the finest ingredients, including 100% Blue Weber Agave, the El Bandido Yankee Añejo is all-natural, with zero color or flavor additives.
  • To El Bandido Yankee Añejo, - here's to the good times, the laughter, and the unbeatable smoothness that accompanies every sip.
  • To find El Bandido Yankee Tequila or learn more, visit elbandidoyankee.com .

Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL

Retrieved on: 
Wednesday, April 3, 2024
Malignancy, MCL, Patient, B-cell lymphoma, Standard of care, Follicular lymphoma, Trial of the century, NHL, IND, Verismo, Clinical trial, Investigational New Drug, Therapy, Mantle cell lymphoma, FDA, NK, DLBCL, B cell, CD19, Food, Bone marrow, Pharmaceutical industry

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310, for the treatment of relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).

Key Points: 
  • Commercially approved CAR T cell therapies have shown impressively high initial response rates in blood cancers.
  • Over time, however, these therapies result in relapse in an estimated 40-50% of patients1.
  • There are currently very limited treatment options for patients with r/r DLBCL who relapse following treatment with commercial CAR T cell therapies.
  • Initiation of the clinical trial is the culmination of years of focused research and diligent work by the Verismo team."

DKNY STEPS UP TO THE PLATE WITH AN ICONIC BILLBOARD AT YANKEE STADIUM

Retrieved on: 
Tuesday, April 2, 2024
Life, NHL, History, NFL, Sport, MLB, DKNY, EVP, G-III Apparel Group, Subway Series, Fashion design

NEW YORK, April 2, 2024 /PRNewswire/ -- DKNY, the iconic New York brand that was founded to celebrate the energy of New York, has entered a multi-faceted, long-term partnership with the team that is the pride of the city — the New York Yankees. DKNY will once again have a presence in Yankee Stadium with a larger than life billboard in right field featuring the new DKNY logo. In 2010, the brand made history as the first fashion brand to advertise on this scale at Yankee Stadium.

Key Points: 
  • DKNY will once again have a presence in Yankee Stadium with a larger than life billboard in right field featuring the new DKNY logo.
  • In 2010, the brand made history as the first fashion brand to advertise on this scale at Yankee Stadium.
  • "DKNY is an iconic New York company, and having its logo prominently displayed in the outfield will provide its brand great exposure at Yankee Stadium throughout the year."
  • The DKNY billboard at Yankee Stadium will be visible beginning on Opening Day, Friday, April 5, 2024.